Valsartan in the treatment of cardiovascular system diseases – effectiveness supported by evidence Review article
Article Sidebar
Published:
Jun 30, 2011
Keywords:
valsartan, arterial hypertension, heart failure, diabetes mellitus
Main Article Content
Abstract
According to current European and Polish guidelines, angiotensin II receptor blockers are regarded as a one of the main five groups of antihypertensive drugs. Many studies have shown that angiotensin II receptor blockers have a favorable effect on the metabolic profile, vascular changes as well as on renal function. In the review, selected clinical studies with valsartan-based therapy confirming its crucial role in the treatment of patients with arterial hypertension, coronary artery disease, after myocardial infarction, with heart failure or coexisting diabetes mellitus are presented.
Article Details
How to Cite
Barylski , M. (2011). Valsartan in the treatment of cardiovascular system diseases – effectiveness supported by evidence. Medycyna Faktow (J EBM), 4(2(11), 29-39. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2533
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2007; 25: 1105-1187.
2. Zasady postępowania w nadciśnieniu tętniczym – 2008 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego oraz Kolegium Lekarzy Rodzinnych w Polsce. Nadciśnienie Tętnicze 2008; 12: C1-30.
3. Kawecka-Jaszcz K., Czarnecka D., Wojciechowska W.: Antagoniści receptora AT1 dla angiotensyny II. Nadciśnienie Tętnicze 2005; supl. A: A1-A15.
4. Markham A., Goa K.L.: Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54(2): 299-311.
5. Pool J., Oparil S., Hedner T. et al.: Dose-responsive antihypertensive efficacy of valsartan, a new angiotensine II-receptor blocker. Clin. Ther. 1998; 20: 1106-1114.
6. Verdecchia P., Angeli F.: Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin. Ther. 2004; 26: 460-472.
7. Palatini P., Mugellini A., Spagnuolo V. et al.; Investigators Group: Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). Blood Press. Monit. 2004; 9(2): 91-97.
8. Julius S., Kjeldsen S.E., Weber M. et al.; VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022-2031.
9. Mochizuki S., Dahlof B., Shimizu M. et al.; Jikei Heart Study group: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369(9571): 1431-1439.
10. Sawada T., Yamada H., Dahlof B. et al.: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur. Heart J. 2009; 30: 2461-2469.
11. KYOTO HEART (ESC 2010 report) [online].
12. Januszewicz A., Prejbisz A.: Miejsce antagonistów receptora angiotensyny II w terapii nadciśnienia tętniczego. Terapia 2010; numer specjalny (maj): 3-8.
13. Januszewicz A., Prejbisz A.: Leczenie nadciśnienia tętniczego walsartanem – praktyczne wskazania na podstawie wytycznych. Terapia 2010; numer specjalny (listopad): 3-9.
14. Grabowski M., Filipiak K.J., Opolski G.: Antagoniści receptora dla angiotensyny II w niewydolności serca – przegląd badań klinicznych. Przew. Lek. 2005; 3: 40-46.
15. Filipiak K.J., Opolski G.: Leki hamujące układ renina-aldosteron. Urban&Partner, Wrocław 2001.
16. Cohn J.N., Tognoni G.; Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001; 345(23): 1667-1675.
17. Latini R., Masson S., Anand I. et al.: Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106: 2454-2458.
18. Kubica J., Grześk G., Kubica A. et al.: Od patofizjologii do terapii – rola antagonistów receptora angiotensynowego AT1 w leczeniu chorych z przewlekłą niewydolnością serca. Cardiovascular Forum 2007; 12(1-2): 3-12.
19. Pfeffer M.A., McMurray J.J., Velazquez E.J. et al.: Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N. Engl. J. Med. 2003; 349: 1893-1906.
20. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 2008; 29(19): 2388-2442.
21. Redon J., Cifkova R., Laurent S. et al.: The metabolic syndrome in hypertension: European society of hypertension position statement. J. Hypertens. 2008; 26: 1891-1900.
22. McMurray J.J., Holman R.R., Haffner S.M. et al.: Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 2010; 362: 1477-1490.
23. Viberti G., Wheeldon N.M.; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106(6): 672-678.
2. Zasady postępowania w nadciśnieniu tętniczym – 2008 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego oraz Kolegium Lekarzy Rodzinnych w Polsce. Nadciśnienie Tętnicze 2008; 12: C1-30.
3. Kawecka-Jaszcz K., Czarnecka D., Wojciechowska W.: Antagoniści receptora AT1 dla angiotensyny II. Nadciśnienie Tętnicze 2005; supl. A: A1-A15.
4. Markham A., Goa K.L.: Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54(2): 299-311.
5. Pool J., Oparil S., Hedner T. et al.: Dose-responsive antihypertensive efficacy of valsartan, a new angiotensine II-receptor blocker. Clin. Ther. 1998; 20: 1106-1114.
6. Verdecchia P., Angeli F.: Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin. Ther. 2004; 26: 460-472.
7. Palatini P., Mugellini A., Spagnuolo V. et al.; Investigators Group: Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). Blood Press. Monit. 2004; 9(2): 91-97.
8. Julius S., Kjeldsen S.E., Weber M. et al.; VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022-2031.
9. Mochizuki S., Dahlof B., Shimizu M. et al.; Jikei Heart Study group: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369(9571): 1431-1439.
10. Sawada T., Yamada H., Dahlof B. et al.: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur. Heart J. 2009; 30: 2461-2469.
11. KYOTO HEART (ESC 2010 report) [online].
12. Januszewicz A., Prejbisz A.: Miejsce antagonistów receptora angiotensyny II w terapii nadciśnienia tętniczego. Terapia 2010; numer specjalny (maj): 3-8.
13. Januszewicz A., Prejbisz A.: Leczenie nadciśnienia tętniczego walsartanem – praktyczne wskazania na podstawie wytycznych. Terapia 2010; numer specjalny (listopad): 3-9.
14. Grabowski M., Filipiak K.J., Opolski G.: Antagoniści receptora dla angiotensyny II w niewydolności serca – przegląd badań klinicznych. Przew. Lek. 2005; 3: 40-46.
15. Filipiak K.J., Opolski G.: Leki hamujące układ renina-aldosteron. Urban&Partner, Wrocław 2001.
16. Cohn J.N., Tognoni G.; Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001; 345(23): 1667-1675.
17. Latini R., Masson S., Anand I. et al.: Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106: 2454-2458.
18. Kubica J., Grześk G., Kubica A. et al.: Od patofizjologii do terapii – rola antagonistów receptora angiotensynowego AT1 w leczeniu chorych z przewlekłą niewydolnością serca. Cardiovascular Forum 2007; 12(1-2): 3-12.
19. Pfeffer M.A., McMurray J.J., Velazquez E.J. et al.: Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N. Engl. J. Med. 2003; 349: 1893-1906.
20. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 2008; 29(19): 2388-2442.
21. Redon J., Cifkova R., Laurent S. et al.: The metabolic syndrome in hypertension: European society of hypertension position statement. J. Hypertens. 2008; 26: 1891-1900.
22. McMurray J.J., Holman R.R., Haffner S.M. et al.: Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 2010; 362: 1477-1490.
23. Viberti G., Wheeldon N.M.; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106(6): 672-678.